Orion (OEC)

NYSE Mercato chiuso

Orion S.A. is a global producer of carbon black, a finely divided form of carbon used to change the strength, durability, conductivity, colour, and processing characteristics of industrial materials. The company supplies customers across automotive, tire, coatings, plastics, printing, battery, and other specialty markets, making it part of the chemical supply chain behind many everyday and industrial products.

Orion reports its business through two main segments: Rubber Carbon Black and Specialty Carbon Black. Rubber Carbon Black is the larger revenue contributor and is primarily used to reinforce tires and mechanical rubber goods, where it helps improve wear resistance, tensile strength, and overall performance. Demand in this segment is closely tied to tire production, vehicle use, replacement tire cycles, and broader industrial activity.

The Specialty Carbon Black segment serves higher-value applications where carbon black functions as a pigment or performance additive. These products are used in coatings, inks, polymers, cables, conductive compounds, and other applications that require specific colour, electrical, or technical properties. Specialty grades can be more customized than standard rubber grades, giving Orion exposure to markets where material performance is a key purchasing factor.

The company operates internationally, with a significant revenue base in Europe and particularly Germany, according to its reported geographic mix. Orion’s position is shaped by manufacturing scale, technical know-how, customer qualification requirements, and the need to meet environmental and quality standards in a heavily regulated chemicals industry.

6.72 USD
6.00 USD
−0.46 (-6.41%)
Fuori orario

Ultimo aggiornamento

Capitalizzazione
378.93M
P/U
P/FCF operativo
10.8
P/Ricavi
0.21
Valore d'impresa
1.34B
Settore
Settore industriale
Indirizzo
1700 CITY PLAZA DRIVE, SUITE 300, SPRING, TX, 77389
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2026

23 apr 2026, 11:00 AM
GlobeNewswire Inc.

Gabelli Hosts 17th Annual Specialty Chemicals Symposium

24 feb 2026, 14:00 PM
GlobeNewswire Inc.

Orion Group Interim Report January–September 2025

28 ott 2025, 11:00 AM
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–syyskuu 2025

28 ott 2025, 11:00 AM
GlobeNewswire Inc.

Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2025

18 lug 2025, 11:00 AM
GlobeNewswire Inc.

Sisäpiiritieto: Orion parantaa näkymäarviota vuodelle 2025

09 lug 2025, 12:00 PM
GlobeNewswire Inc.

Orion ja Glykos laajentavat tutkimusyhteistyö- ja lisenssisopimustaan seuraavan sukupolven vasta-ainekonjugaattien kehittämiseksi

17 giu 2025, 08:00 AM
GlobeNewswire Inc.

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

17 giu 2025, 08:00 AM
GlobeNewswire Inc.

Orionin yhteistyökumppani MSD laajentaa opevesostaatin kliinistä kehitysohjelmaa naisten syöpiin

21 mag 2025, 06:30 AM
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2025

23 apr 2025, 11:00 AM
GlobeNewswire Inc.

Lääketeollisuus luovutti hallitukselle arvolupauksen: miljarditason investoinnit vuoteen 2030 mennessä

21 mar 2025, 12:00 PM
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

07 gen 2025, 08:00 AM
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee Kiinassa kolmatta indikaatiota darolutamidille

07 gen 2025, 08:00 AM
GlobeNewswire Inc.

Orion ja Abilita Therapeutics sopivat tutkimusyhteistyöstä ja lisenssisopimusoptiosta innovatiivisten vasta-ainehoitojen kehittämiseksi

18 dic 2024, 16:00 PM
GlobeNewswire Inc.

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

18 dic 2024, 16:00 PM
GlobeNewswire Inc.

Sisäpiiritieto: Orion lopettaa ODM-111-kehitysohjelman perustuen molekyylin liian kapeaan terapeuttiseen ikkunaan

24 ott 2024, 18:50 PM
GlobeNewswire Inc.

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

24 ott 2024, 18:50 PM
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee EU:ssa kolmatta indikaatiota darolutamidille

14 ott 2024, 10:00 AM
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

14 ott 2024, 10:00 AM
GlobeNewswire Inc.

Darolutamidi yhdessä ADT-hoidon kanssa pienensi merkitsevästi (46 prosentilla) syövän etenemisen tai kuoleman riskiä verrattuna lumelääkkeen ja ADT:n yhdistelmään levinnyttä hormonisensitiivistä eturauhassyöpää sairastavilla potilailla

16 set 2024, 10:30 AM
Capitalizzazione
378.93M
Valore d'impresa
1.34B
P/U
P/VL
1
P/Ricavi
0.21
Valore d'impresa / EBITDA
6.34
EV / Ricavi
0.75
Utile per azione
-1.58
Rendimento del dividendo
1.24%
P/FCF operativo
10.8
P/Flusso di cassa
1.87
Free cash flow
35.1M
ROE (rend. patrimonio)
-23.48%
ROA (rend. attivo)
-4.61%
Debito / Patrimonio netto
2.67
Indice di liquidità corrente
1
Indice di liquidità rapida
0.62
Liquidità
0.08
Vol. medio
460.75K
Prezzo di riferimento fondamentale
6.72

Conto economico

Voce 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Ricavi 459.5M 411.7M 450.9M 466.4M 477.7M
Utile lordo 79.2M 77.7M 85.6M 98.4M 98.1M
Risultato operativo 11.4M 13.5M -52.3M 32.1M 31.2M
MOL 44.1M 41.3M 62.2M 64.1M 62.7M
Utile netto -9.9M -21.1M -67.1M 9M 9.1M
EPS base -0.18 -0.37 -1.2 0.16 0.16
EPS diluito -0.18 -0.37 -1.2 0.16 0.16

Stato patrimoniale

Voce 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Attivo totale 1.93B 1.91B 1.96B 2.02B 1.97B
Passivo totale 1.55B 1.52B 1.56B 1.56B 1.5B
Patrimonio netto 379.5M 384.6M 401.8M 466.5M 466.1M
Liquidità e equivalenti 50.5M 60.7M 51.3M 42.6M 37.5M
Attivo corrente 661.5M 643.8M 683.5M 682.5M 688.6M
Passivo corrente 659.7M 626.4M 635.3M 620.8M 601.9M

Flusso di cassa

Voce 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Flusso di cassa operativo -12.4M 92.9M 68.8M 53.7M 400K
Flusso di cassa da investimenti -36.1M -48.7M -40.9M -42.2M -29.2M
Flusso di cassa da finanziamenti 39.6M -35.7M -19.5M -7.8M 21.8M
Variazione di liquidità -8.9M 8.5M 8.4M 3.7M -7M
Tipo Documento Data Collegamento
edgar index 8-K — Orion S.A. Visualizza documento
edgar index 10-Q — Orion S.A. Visualizza documento
eight k text 8-K — 8-K Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
form 4 Form 4 — Niewiem Sandra Visualizza documento
form 4 Form 4 — Painter Corning F. Visualizza documento
form 4 Form 4 — Puckett Jonathan A. Visualizza documento
form 4 Form 4 — Quinones Carlos Visualizza documento
form 4 Form 4 — Riveros Pedro Visualizza documento
edgar index ARS — Orion S.A. Visualizza documento
edgar index DEF 14A — Orion S.A. Visualizza documento
edgar index 8-K — Orion S.A. Visualizza documento
eight k text 8-K — 8-K Visualizza documento
edgar index PRE 14A — Orion S.A. Visualizza documento
edgar index 8-K — Orion S.A. Visualizza documento
eight k text 8-K — 8-K Visualizza documento
edgar index 8-K — Orion S.A. Visualizza documento
eight k text 8-K — 8-K Visualizza documento
edgar index 8-K — Orion S.A. Visualizza documento
edgar index SCHEDULE 13G — Orion S.A. Visualizza documento
eight k text 8-K — 8-K Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
form 4 Form 4 — Niewiem Sandra Visualizza documento
form 4 Form 4 — Niewiem Sandra Visualizza documento
form 4 Form 4 — Niewiem Sandra Visualizza documento
form 4 Form 4 — Painter Corning F. Visualizza documento
form 4 Form 4 — Painter Corning F. Visualizza documento
form 4 Form 4 — Painter Corning F. Visualizza documento
form 4 Form 4 — Quinones Carlos Visualizza documento
form 4 Form 4 — Quinones Carlos Visualizza documento
form 4 Form 4 — Quinones Carlos Visualizza documento
form 4 Form 4 — Riveros Pedro Visualizza documento
form 4 Form 4 — Riveros Pedro Visualizza documento
form 4 Form 4 — Riveros Pedro Visualizza documento
edgar index 8-K — Orion S.A. Visualizza documento
edgar index 10-K — Orion S.A. Visualizza documento
eight k text 8-K — 8-K Visualizza documento
ten k section 10-K — business Visualizza documento
ten k section 10-K — mda Visualizza documento
ten k section 10-K — risk_factors Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
form 4 Form 4 — Puckett Jonathan A. Visualizza documento
edgar index 3 — Orion S.A. Visualizza documento
edgar index 8-K — Orion S.A. Visualizza documento
eight k text 8-K — 8-K Visualizza documento
edgar index 8-K — Orion S.A. Visualizza documento
edgar index 10-Q — Orion S.A. Visualizza documento
eight k text 8-K — 8-K Visualizza documento
edgar index 8-K — Orion S.A. Visualizza documento
eight k text 8-K — 8-K Visualizza documento
edgar index 8-K — Orion S.A. Visualizza documento
eight k text 8-K — 8-K Visualizza documento
edgar index 8-K — Orion S.A. Visualizza documento
edgar index 8-K — Orion S.A. Visualizza documento
edgar index 10-Q — Orion S.A. Visualizza documento
edgar index SCHEDULE 13G/A — Orion S.A. Visualizza documento
edgar index 8-K — Orion S.A. Visualizza documento
edgar index SCHEDULE 13G/A — Orion S.A. Visualizza documento
edgar index 3 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
edgar index 4 — Orion S.A. Visualizza documento
form 4 Form 4 — GALVIN KERRY A Visualizza documento